ArticleEuropean journal of medical research2025
Prognostic analysis of cerebral microbleeds in patients with large artery atherosclerotic stroke without thrombolytic therapy.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThis study aims to investigate the prognostic implications of cerebral microbleeds (CMBs) in patients with large artery atherosclerotic stroke (LAAS) without thrombolytic therapy, mainly focusing on the association between CMBs and clinical outcomes, such as recurrent ischemic stroke (IS), intracranial hemorrhage (ICH), and all-cause mortality.
methodsA retrospective cohort study was conducted on 353 LAAS patients (January 2016-October 2021) at the Affiliated Hospital of Qingdao University. All underwent susceptibility-weighted imaging (SWI) and received single or dual antiplatelet therapy. CMBs were classified by location (lobar, deep, and infratentorial) and severity. Kaplan-Meier survival analysis and Cox regression models were used to assess endpoint events.
resultsAmong the 353 patients, 147 had CMBs. Significant differences in age, fasting blood glucose levels, and history of hypertension were observed between patients with and without CMBs. Age and hypertension were identified as independent risk factors for CMBs. Patients with CMBs had a significantly higher incidence of recurrent IS and all-cause mortality compared to those without CMBs. Recurrent IS, ICH, and all-cause mortality were defined as the primary endpoint events in this study. The mean time to endpoint events was shorter in patients with CMBs (59.2 months) compared to those without CMBs (79.1 months). The location of CMBs influenced the prognosis, with deep or infratentorial CMBs associated with higher mortality. However, CMB location does not significantly influence the risk of IS or ICH. Single or dual antiplatelet therapy did not significantly alter the risk of endpoint events in patients with CMBs.
conclusionsThe presence of CMBs, particularly in deep or infratentorial regions, significantly worsens the prognosis of LAAS patients without thrombolytic therapy. Patients with CMBs have a higher risk of recurrent IS and all-cause mortality, but no significant difference in ICH incidence compared to those without CMBs. CMB burden had no differential effect on the efficacy of single antiplatelet therapy (SAPT) or double antiplatelet therapy (DAPT). Further prospective studies are necessary to validate these findings and explore alternative therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.